Inactivation of harmful tumour-associated proteolysis by nanoparticulate system

International Journal of Pharmaceutics

Volumn 381, Issue 2, 2009, Pages 106-112

  Kos, Janko ^a,b   Obermajer, Nataša ^a   Doljak, Bojan ^a   Kocbek, Petra ^a   Kristl, Julijana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Antibody; Cathepsin; Cystatin; Cytokeratin; Nanoparticle; Plasmin

Indexed keywords

CATHEPSIN B; CYSTATIN; CYTOKERATIN ANTIBODY; NANOCARRIER; PLASMIN; POLYGLACTIN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENDOSOME; ENZYME INACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CACO-2 CELLS; CATHEPSIN B; CELL ADHESION; COCULTURE TECHNIQUES; CYSTATINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; GLYCOLATES; HUMANS; IMMUNOCONJUGATES; KERATINS; LYSOSOMES; NANOPARTICLES; NEOPLASM INVASIVENESS; PLASMINOGEN; SURFACE PROPERTIES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 70349293659     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.04.037     Document Type: Article

References (33)

1. Cegnar M., Premzl A., Zavašnik-Bergant V., Kristl J., and Kos J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumour cells. Exp. Cell. Res. 301 (2004) 223-231
2. Cegnar M., Kos J., and Kristl J. Cystatin incorporated in poly(lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur. J. Pharm. Sci. 22 (2004) 357-364
3. Cegnar M., Kristl J., and Kos J. Nanoscale polymer carriers to deliver chemotherapeutics to tumours. Exp. Opin. Biol. Ther. 5 (2005) 1557-1569
4. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloprotease inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
5. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., and Rømer J. Plasminogen activation and cancer. Thromb. Haemost. 93 (2005) 676-681
6. Ditzel H., Garrigues U., Andersen C., Larsen M., Garrigues H., Svejgaard A., Hellström I., Hellström K., and Jensenius J. Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 8110-8115
7. Doljak B., Obermajer N., Jamnik P., and Kos J. Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells. Cancer Lett. 267 (2008) 75-84
8. Ellis V., Behrendt N., and Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 266 (1991) 12752-12758
9. Gonias S., Young W.J., and Fox J. Cleavage of recombinant murine interferon-gamma by plasmin and miniplasmin. J. Interferon Res. 9 (1989) 517-529
10. Honey K., and Rudensky A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3 (2003) 472-482
11. Kasper M., and Singh G. Epithelial lung cell marker: current tools for cell typing. Histol. Histopathol. 10 (1995) 155-169
12. Kocbek P., Obermajer N., Cegnar M., Kos J., and Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control Release 120 (2007) 18-26
13. Kos J., Dolinar M., and Turk V. Isolation and characterisation of chicken L- and H-kininogens and their interaction with chicken cysteine proteineses and papain. Agents Actions 38 (1992) 331-339
14. Kos J., and Lah T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5 (1998) 1349-1361
15. Kos J., and Lah T. Cystatins in cancer. In: Žerovnik E., Kopitar Jerala N., and Uversky V. (Eds). Human Stefins and Cystatins (2006), Nova Science Publisher, New York 153-165
16. Kos, J., Jevnikar, Z., Obermajer, N., 2009. The role of cathepsin X in cell signalling. Cell Adhes. Migrat., 3, 164/166.
17. Kralovich K., Li L., Hembrough T., Webb D., Karns L., and Gonias S. Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J. Protein Chem. 17 (1998) 845-854
18. Lopez-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fabregas P., Jardi{dotless} M., Merton E., Miles L., and Felez J. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am. J. Hematol. 72 (2003) 234-242
19. Lyons A., and Ashman L. The effect of recombinant cytokines on the proliferative potential and phenotype of cells of the human myelomonocytic leukaemia line, RC-2A. Leuk. Res. 12 (1988) 659-666
20. Mohamed M.M., and Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6 (2006) 764-775
21. Sameni M., Moin K., and Sloane B.F. Imaging proteolysis by living human breast cancer cells. Neoplasia 2 (2000) 496-504
22. Nori A., and Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 57 (2004) 609-636
23. Obermajer N., Kocbek P., Repnik U., Kužnik A., Kristl J., Cegnar M., and Kos J. Immuno-nanoparticles: an effective tool to impair harmful proteolysis in invasive breast tumour cells. FEBS J. 274 (2007) 4416-4427
24. Pasche B., Ouimet H., Francis S., and Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 83 (1994) 404-414
25. Premzl A., Zavašnik Bergant V., Turk V., and Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix. Exp. Cell Res. 283 (2003) 206-214
26. Premzl A., Turk V., and Kos J. Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation of endothelial cells in vitro. J. Cell. Biochem. 97 (2006) 1230-1240
27. Schmitt M., Jänicke F., and Graeff H. Tumour associated proteases. Fibrinolysis 6 (1992) 3-26
28. Tan X., Egami H., Nozawa F., Abe M., and Baba H. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. Int. J. Oncol. 28 (2006) 369-374
29. Turk V., and Turk B. Lyzosomal cystein proteases: facts and opportunities. EMBO J. 20 (2001) 4629-4633
30. Turk B., Turk D., and Salvasen G.S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Dis. 8 (2002) 1623-1637
31. Turk V., Kos J., and Turk B. Cysteine cathepsins (proteases)-on the main stage of cancer?. Cancer Cell 5 (2004) 409-410
32. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5 (2006) 785-799
33. Van Noorden, C.J.F., Jonges, T.G.N., Van Marle, J., Bissell, E.R., Griffini, P., Jans, M., Snel, J., Smith, R.E. 1998. Heterogenous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin, B. Clin Exp Metastasis 16,159/167.